Skip to content

A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19)

Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003142
Enrollment
Unknown
Registered
2020-03-20
Start date
2020-03-23
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for patients with COVID-19 of the Proposal of Diagnosis and Treatment of COVID-19; (2) Aged 18-85 years; (3) To agree to participate in the study and sign the informed consent

Exclusion criteria

Exclusion criteria: (1) Critical patients; (2) TCM diagnosis of yang deficiency syndrome, manifested as limb warm, thin stools, chills, etc.; (3) Patients who cannot guarantee compliance during treatment, and patients who are difficult to administer by oral or nasal route; (4) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19; (5) Pregnant and mothers, those who have a pregnancy plan, and those who have a positive urine pregnancy test; (6) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study; (7) People who have been allergic to Chinese medicine or intolerant to taking medicine. (8) Patients are participating in other COVID-19 clinical trials.

Design outcomes

Secondary

MeasureTime frame
Total hospitalized time;side effects associated with interventions;

Primary

MeasureTime frame
Inflammation absorption on Chest CT;

Countries

China

Contacts

Public ContactZhongde Zhang

Guangdong Provincial Hospital of Chinese Medicine

doctorzzd99@163.com+86 13903076359

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026